Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same

a technology for autoimmune diseases and screening methods, applied in the direction of immunodeficiency syndrome, drug composition, sense disorder, etc., can solve the problems of no well-established therapeutic method, and nothing has been known in relation to the effect of rbap48 on improving the pathological condition of patients, and achieve excellent preventive or therapeutic effects

Inactive Publication Date: 2005-02-03
KOWA CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] In view of the foregoing, the present inventor has, performed extensive studies and confirmed that RBAp48 is one factor that is expressed in cells of the salivary glands—a target organ of autoimmune diseases, particularly Sjögren's syndrome—when estrogen is deficient, and that apoptosis of the salivary gland cells is induced by incorporating RBAp48 into the cells. On the basis of these findings, the present inventors have found that autoimmune diseases can be diagnosed by determining RBAp48 level in gland tissues; screening of candidate preventive or therapeutic agents for autoimmune diseases can be performed through determination of the RBAp48 production suppressing effect or RBAp48 production inhibitory effect of a sample; and an RBAp48 production suppressor or inhibitor exhibits excellent preventive or therapeutic effect on autoimmune diseases such as Sjögren's syndrome and thus is useful as a drug for autoimmune diseases, thereby leading to completion of the present invention.

Problems solved by technology

However, according to current theory, when the self tolerance is lost for some reason, the individual develops an autoimmune disease.
Therefore, symptomatic approaches have been major measures for treatment of autoimmune diseases, and practically, there is no well-established therapeutic method as yet.
However, nothing has been known in relation to what effect RBAp48 exerts on improvement of pathological conditions of patients who suffer autoimmune diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same
  • Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same
  • Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

Apoptosis of salivary Gland Cells of Normal Mice

[0028] C57BL / 6 mice and estrogen receptor knockout (ERαKO) mice were ovariectomized (Ovx), and salivary gland cells of each mouse were observed over time for six weeks after the ovariectomy in terms of apoptosis. Slices of the salivary gland cells were stained through TUNEL, and whether or not apoptosis occurred was evaluated from the stain index (TUNEL index). Sham operation groups (Sham), to which Ovx had not been performed, were used as controls. As a result, as shown in FIG. 1, transient apoptosis was observed from two to three weeks after Ovx in the salivary gland cells of the C57BL / 6 mice to which ovariectomy had been performed. In contrast, in the salivary gland cells of the ERαKO mice, increase in apoptotic cells was not observed. Thus, apoptosis of salivary gland cells was confirmed to involve estrogen deficiency.

example 2

Apoptosis Induction of Cultured Cells

[0029] Cells of each of the following cell lines were cultured through a routine method; mouse salivary gland cell lines (MSG:B6 and ERαKO); human salivary gland cell line (HSG); human breast cancer cultured-cell line (MCF-7); human acute T cell leukemia cell line (Jurkat); and human colon cancer cultured-cell lines (HT-29 and Colo201). The cultured cells were reacted with tamoxifen (Tam, final concentration: 10−7 M), an antagonist of estrogen. The resultant cells were observed in terms of Tam's effect on apoptosis and saliva-gland-specific antigens, and activity of apoptosis-related proteases (e.g., caspase) was investigated. Separately, the above cultured cells were reacted with staurosporin (an apoptosis inducer, final concentration: 10−6 M), and the resultant cells were used as a positive control group. Forty-eight hours after the addition of Tam, apoptosis of the cells was determined by means of a flow cytometer, by use of Annexin-V-FITC. A...

example 3

Identification of the Genes which Exhibit Enhanced Expression by Anti-Estrogen Effect

[0030] HSG cells were stimulated by Tam to thereby cause expression of mRNAs. mRNAs which exhibited enhanced expression as compared with those of non-stimulated HSG cells were extracted through a routine method and isolated through the differential display method (RNA image kit, Gene Hunter™, Toyobo). The thus-obtained DNA fragments were transferred into E. Coli for cloning. The thus-obtained mRNAs were investigated through northern blotting (FIG. 3) by use of HSG cells and the isolated DNA fragments serving as probes, to thereby determine mRNAs which exhibit enhanced expression by tamoxifen (final concentration: 10−7 M), and the expression was reduced by addition of estradiol (final concentration: 10−9 M). The amino acid sequences of the DNA fragments were determined through a routine sequencing method. The DNA fragments were identified to be the RBAp48 gene. Two hours after Tam stimulation, the H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Inhibitionaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to a method for treating autoimmune diseases comprising administering RBAp48 production suppressor or inhibitor; a screening method for a preventive or therapeutic agent for autoimmune diseases comprising determining RBAp48 production suppressing effect or inhibitory effect of a sample; a diagnosis agent or a diagnosing kit for autoimmune diseases containing a reagent for measuring RBAp48 level in gland tissue; and a diagnosis method for autoimmune diseases comprising measuring RBAp48 level in gland tissue.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates to a method for treating autoimmune diseases, a screening method for a preventive or therapeutic agent for autoimmune diseases, and a diagnostic method for autoimmune diseases. [0003] 2. Background Art [0004] Autoimmune diseases are pathological conditions caused by antibodies (autoantibodies) which are formed against components that constitute an individual's own body (autoantigens), or by T cells formed against such autoantigens. Various types of autoimmune diseases have been known: Some affect specific organs, and some others develop systemically. Autoantibodies provide a broad range of actions. Specifically, autoantibodies destruct cells (as in, e.g., autoimmune hemolytic anemia); impair physiological functions (as in, e.g., myasthernia gravis); excessively stimulate receptors (as in, e.g., Basedow's disease (Graves' disease)); or form antigen-antibody complexes (immune complexes) a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/50A61K45/00A61P7/06A61P21/04A61P27/02A61P29/00A61P37/02C12N15/09C12Q1/02C12Q1/68G01N33/15G01N33/564
CPCG01N33/564G01N2800/24G01N2500/00A61P7/06A61P21/04A61P27/02A61P29/00A61P37/02
Inventor HAYASHI, YOSHIO
Owner KOWA CO LTD